Abstract
AbstractImmune checkpoint inhibitors have established in the treatment of malignant melanoma and have significantly improved prognosis in advanced tumour stages. As they interfere with immunoregulatory pathways by blocking checkpoints, nonspecific activation of the immune system can result in the development of immune‐related adverse events. Hepatitis occurs in 25%–30% of combination therapy and usually occurs 6–12 weeks after initiation of treatment. In most cases, the adverse event can be successfully treated with glucocorticosteroids but sometimes this is not sufficient, and further therapy is required. We report on a life‐threatening course of immune‐mediated hepatitis in a 39‐year‐old woman with metastatic melanoma, whom we were finally able to treat successfully with a combination therapy consisting of prednisolone, mycophenolate‐mofetil, extracorporeal photopheresis and infliximab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
